Organisation paid for research Program year 2024 Source: CMS Open Payments

C-1 Headlands LLC

Neither a doctor nor a teaching hospital

Research payments

$4,154,489

800 payments

Through program year 2024, C-1 Headlands LLC is reported as receiving $4,154,489 in research payments, across 800 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $297 1
2023 Research $26,705 17
2022 Research $194,165 116
2021 Research $736,470 278
2020 Research $2,089,475 370
2019 Research $1,107,377 18

Breakdown

Who paid Research payments · program years 2019–2024
  1. Allergan Inc. $2,878,081 266 payments
  2. AbbVie, Inc. $486,039 333 payments
  3. VIVUS, Inc. $268,665 41 payments
  4. Eli Lilly and Company $203,074 6 payments
  5. Evofem Biosciences, Inc. $79,306 42 payments
  6. Eisai Inc. $62,565 27 payments
  7. Radius Health, Inc. $56,740 25 payments
  8. GlaxoSmithKline, LLC. $40,332 9 payments
  9. Kowa Research Institute, Inc. $31,064 29 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $22,951 7 payments
Studies the money was for Research payments · program years 2019–2024
  1. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $1,309,936 103 payments
  2. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $1,067,090 10 payments
  3. A Phase IV Safety and Efficacy of VI-0521 in Obese Adolescents $268,665 41 payments
  4. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $230,168 74 payments
  5. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $191,474 5 payments
  6. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $110,628 95 payments
  7. M16-100 $93,769 56 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $91,518 21 payments
  9. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $71,732 64 payments
  10. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $62,565 27 payments
What the money was spent on Research payments · program years 2019–2024
  1. Other $268,665 41 payments
  2. Professional salary support $75,355 38 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record